Anabolic Therapies

The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1–34) is the first US Food and Drug Administration–approved anabolic therapy. Its use has been limited by the need for s...

Descripción completa

Detalles Bibliográficos
Autores principales: Lane, Nancy E., Silverman, Stuart L.
Formato: Texto
Lenguaje:English
Publicado: Current Science Inc. 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841260/
https://www.ncbi.nlm.nih.gov/pubmed/20425087
http://dx.doi.org/10.1007/s11914-010-0005-4
_version_ 1782179100759162880
author Lane, Nancy E.
Silverman, Stuart L.
author_facet Lane, Nancy E.
Silverman, Stuart L.
author_sort Lane, Nancy E.
collection PubMed
description The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1–34) is the first US Food and Drug Administration–approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone–related protein PTHrP, a calcium-regulating hormone similar to PTH.
format Text
id pubmed-2841260
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Current Science Inc.
record_format MEDLINE/PubMed
spelling pubmed-28412602010-03-26 Anabolic Therapies Lane, Nancy E. Silverman, Stuart L. Curr Osteoporos Rep Article The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1–34) is the first US Food and Drug Administration–approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone–related protein PTHrP, a calcium-regulating hormone similar to PTH. Current Science Inc. 2010-02-19 2010 /pmc/articles/PMC2841260/ /pubmed/20425087 http://dx.doi.org/10.1007/s11914-010-0005-4 Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Lane, Nancy E.
Silverman, Stuart L.
Anabolic Therapies
title Anabolic Therapies
title_full Anabolic Therapies
title_fullStr Anabolic Therapies
title_full_unstemmed Anabolic Therapies
title_short Anabolic Therapies
title_sort anabolic therapies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841260/
https://www.ncbi.nlm.nih.gov/pubmed/20425087
http://dx.doi.org/10.1007/s11914-010-0005-4
work_keys_str_mv AT lanenancye anabolictherapies
AT silvermanstuartl anabolictherapies

Ejemplares similares